Companies / Ipsen
Ipsen
CompanyIpsen is a global biopharmaceutical company focused on oncology, rare disease, and neuroscience. It brings medicines to patients in more than 80 countries and operates with global development hubs.
- Trials
- 288
- Recruiting
- 18
- Completed
- 204
- With results
- 102
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Total |
|---|---|---|---|---|---|---|---|
| Phase 1 | — | — | 1 | 12 | 3 | 1 | 17 |
| Phase 1/2 | 4 | — | 2 | 2 | 2 | — | 10 |
| Phase 2 | 1 | — | 2 | 24 | 19 | 1 | 47 |
| Phase 2/3 | — | 1 | — | 5 | — | — | 6 |
| Phase 3 | 4 | — | 5 | 55 | 9 | — | 73 |
| Phase 4 | — | — | — | 16 | 1 | 1 | 18 |
| Not applicable | — | — | — | 1 | — | — | 1 |
| Unknown | 9 | — | 5 | 89 | 8 | 5 | 116 |
Trials started per year
Conditions studied, by phase
| Condition | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | — | 1 | 3 | 1 | 7 | 3 | — | 19 | 34 |
| Prostatic Neoplasms | 1 | — | 4 | — | 7 | 2 | — | 9 | 23 |
| Neuroendocrine Tumors | — | 1 | 2 | — | 2 | 1 | — | 11 | 17 |
| Muscle Spasticity | — | 1 | — | — | 2 | 2 | 1 | 9 | 15 |
| Carcinoma, Renal Cell | — | — | 2 | — | — | — | — | 9 | 11 |
| Torticollis | — | — | 1 | — | 6 | — | — | 4 | 11 |
| Liver Cirrhosis, Biliary | — | — | — | — | 4 | — | — | 3 | 7 |
| Stroke | — | — | — | — | 1 | 3 | — | 2 | 6 |
| Breast Neoplasms | 1 | 1 | 2 | — | — | — | — | 1 | 5 |
| Diarrhea | — | — | — | 1 | 3 | 1 | — | — | 5 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Ipsen | 288 | 79 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Erasmus Medical Center | 1 |
| 2 | INC Research Limited | 1 |
| 3 | University Medical Center Groningen | 1 |
| 4 | University of Oklahoma | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Botulinum Toxins, Type A | 47 |
| 2 | abobotulinumtoxinA | 46 |
| 3 | lanreotide | 25 |
| 4 | Triptorelin Pamoate | 17 |
| 5 | 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid | 8 |
| 6 | Data Collection | 8 |
| 7 | Ginkgo biloba extract | 7 |
| 8 | mecasermin | 6 |
| 9 | irinotecan sucrosofate | 5 |
| 10 | irosustat | 5 |
Evidence
- Results reported
- 50%102 of 204 completed
- Published
- 10.3%21 of 204 completed
- Primary endpoint met
- 49.4%44 of 89 analyses
- Median months to report
- 18
Documents disclosed
Trial profile
- Median enrollment
- 115
- Median duration
- 27.5months
- Countries
- 64
- Study sites
- 6120
Who is enrolled
Median enrollment by phase
- Phase 1
- 34
- Phase 1/2
- 63
- Phase 2
- 49
- Phase 2/3
- 69
- Phase 3
- 147
- Phase 4
- 121
- Not applicable
- 104
- Unknown
- 162
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Paris | France | 60 |
| 2 | Madrid | Spain | 55 |
| 3 | Barcelona | Spain | 49 |
| 4 | Prague | Czechia | 44 |
| 5 | Toulouse | France | 40 |
| 6 | Marseille | France | 38 |
| 7 | Warsaw | Poland | 38 |
| 8 | Berlin | Germany | 37 |
| 9 | London | United Kingdom | 35 |
| 10 | Houston | United States | 34 |
Terminations
- Terminated
- 42
- Withdrawn
- 8
- Stopped for recruitment
- 8%23 of 288 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07282548 Withdrawn | Withdrawn | Withdrawn prior to enrolment after review of updated safety data | 2031-06-30 |
| NCT06341712 Terminated | Terminated | The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges | 2026-02-27 |
| NCT04003519 Withdrawn | Withdrawn | Study timeline delay, low site feasibility and delay concerns due to COVID-19. | 2023-12-30 |
| NCT05922579 Terminated | Terminated | Significant and complex challenges had since been identified during recent testing phases. After their assessment, Ipsendecided to discontinue development of this motorized device in order to not burden participants. | 2023-12-01 |
| NCT05184231 Withdrawn | Withdrawn | Study wasn't feasible anymore. It was withdrawn on 13 Jan 2023. | 2023-10-31 |
| NCT04609800 Withdrawn | Withdrawn | Unfavorable opinion of IRB/IEC | 2023-05-10 |
| NCT03895463 Withdrawn | Withdrawn | Reassessment of study feasibility | 2023-03-26 |
| NCT04736745 Terminated | Terminated | Sponsor terminated the study due to strategic considerations | 2022-10-28 |
| NCT02592707 Terminated | Terminated | Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up. | 2022-02-22 |
| NCT04632199 Withdrawn | Withdrawn | Business decision not related to any safety or tolerability concern | 2021-12-10 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: